HIV/AIDS Therapy

Gilead cuts AIDS drugs prices in middle-income countries

Published in Vaccine Weekly, August 16th, 2006

AIDS Healthcare Foundation applauded the decision by Gilead Sciences, Inc. to cut the prices for its lifesaving antiretroviral AIDS drugs by almost two-thirds in middle-income countries (MICs) such as Mexico and India.

MICs are not eligible for benefits from many of the same policies, programs and agreements that promote antiretroviral treatment (ART) access in least developed countries (LDCs) where AIDS drug treatment can cost less that $200 annually per person.

As a result, in a middle-income country like Mexico, which has a per capita annual income of approx. $6,000, AIDS drugs for one person cost $8,000 annually.

Least...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2006-08-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry